BULLISHWHALES
BullishWhales · Analysts · Analyst Profile

Paul Choi

Goldman Sachs · Equity Research Analyst

Analyst rating accuracy & track record

Paul Choi does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
GOSSGossamer Bio Inc
Buy$8.00May 2025−92.7%Miss
GOSSGossamer Bio Inc
Buy$7.00Apr 2025−59.4%Miss
VIRVir Biotechnology Inc
Buy$21.00Apr 2025+77.4%Miss
AMRNAmarin Corporation PLC
Sell$7.00Apr 2025−42.6%Miss
LNTHLantheus Holdings Inc
Buy$143.00Dec 2024−44.4%Miss
GOSSGossamer Bio Inc
Buy$8.00Jun 2024+135.8%Miss
GOSSGossamer Bio Inc
Buy$8.00Mar 2024−15.6%Miss
KNSAKiniksa Pharmaceuticals Ltd
Buy$32.00Jul 2023+27.6%Miss
AMRNAmarin Corporation PLC
Sell$1.00Jul 2023+40.7%Hit
FHTXFoghorn Therapeutics Inc
Buy$19.00Jun 2023−29.9%Miss
AMRNAmarin Corporation PLC
Sell$1.50May 2022+8.0%Hit
PMVPPmv Pharmaceuticals Inc
Buy$43.00Sep 2021−55.0%Miss
AMRNAmarin Corporation PLC
Sell$5.00May 2021+75.8%Hit
Go to

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30